Teva Pharmaceutical (TEVA) is trading at new 5-year highs. ・Shares are up more than 40% over the past year. ・The stock has ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teva Pharmaceutical Industries wasn’t one of them. The 10 stocks that ...

Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. As of September 30, the fund reported ...

Teva's big business is selling generic drugs. Essentially, it's the competition for makers of branded drugs once their ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter results were ...

Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00. The company reported strong first-quarter results, with increased revenue and growth in key metrics.

Teva stock climbs past $30 with strong Austedo and Ajovy sales, but shifting Wall Street sentiment may affect its outlook.

S&P upgraded Teva to BB+ and Moody's turned positive, citing falling leverage, stronger cash flow, and branded drug momentum that could support a future investment-grade rating.

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex ...

Investing.com -- Piper Sandler raised its price target on Teva Pharmaceutical Industries to $40 from $30, arguing the ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.

Investing.com -- S&P Global Ratings has upgraded Teva Pharmaceutical Industries Ltd. to ’BB+’ from ’BB’ with a stable outlook ...